We claim:
1. A crystalline form V of salflufenacil acetonitrile solvate, which in a powder Xray diffraction pattern expressed in terms of 2? (±0.2°) angles;
wherein the powder X-ray diffraction pattern comprising at least three peaks
5 selected from the group comprising 6.3 ± 0.2, 6.6 ± 0.2, 9.8 ± 0.2, 10.6 ± 0.2,
10.8 ± 0.2, 12.5 ± 0.2, 12.7 ± 0.2, 15.9 ± 0.2, 16.2 ± 0.2, 17.6 ± 0.2, 18.5 ± 0.2,
19.0 ± 0.2, 19.7 ± 0.2, 20.4 ± 0.2, 20.7 ± 0.2, 21.6 ± 0.2, 21.9 ± 0.2, 22.6 ± 0.2,
23.3 ± 0.2, 23.6 ± 0.2, 24.1 ± 0.2 25.5 ± 0.2, 26.0 ± 0.2, 27.0 ± 0.2, 27.4 ± 0.2,
28.1 ± 0.2, 28.4 ± 0.2, 29.1 ± 0.2, 29.4 ± 0.2, 29.9 ± 0.2, 30.3 ± 0.2, 30.7 ± 0.2,
10 31.0 ± 0.2, 31.4 ± 0.2, 31.8 ± 0.2, 32.2 ± 0.2, 33.0 ± 0.2.
2. The crystalline form V as claimed in claim 1 is characterized by differential
scanning calorimetry endotherm curve exhibiting at least three characteristics
endotherms in the range of about 70°C to 80°C, 80°C to 90°C and 185°C to
195°C.
15 3. The crystalline form V as claimed in claim 1 exhibits an Fourier-Transform
Infra-Red (FTIR) spectrum with characteristic peaks at wavenumbers 3575,
3488, 3061,2980, 2880, 1706, 1678, 1614, 1588, 1504, 1427, 1393, 1345, 1253,
1222, 1205, 1186, 1108, 1068, 1049, 998, 906, 815, 734, 703, 694, 662,
625,611, 528, 471 ±4 cm-1
.
20 4. A crystalline form VI of saflufenacil propionitrile, which in a powder X-ray
diffraction pattern expressed in terms of 2? (±0.2°) angles;
wherein the powder X-ray diffraction pattern comprising at least three peaks
selected from the group comprising 5.2 ± 0.2, 10.2 ± 0.2, 10.7 ± 0.2, 13.9 ± 0.2,
15.2 ± 0.2, 16.4 ± 0.2, 18.0 ± 0.2, 20.4 ± 0.2, 20.7 ± 0.2, 21.7 ± 0.2, 22.0 ± 0.2,
25 22.2 ± 0.2, 22.5 ± 0.2, 23.1 ± 0.2, 23.3 ± 0.2, 25.6 ± 0.2, 27.0 ± 0.2, 27.3 ± 0.2,
28.73 ± 0.2, 30.4 ± 0.2, 30.8 ± 0.2, 33.6 ± 0.2, 36.1 ± 0.2.
5. The crystalline form VI as claimed in claim 4 is characterized by differential
scanning calorimetry endotherm curve having at least three characteristi